|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/04/17 Actinium Pharmaceuticals, Inc. 10-Q 6/30/17 60:3.8M Edgar Agents LLC/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 369K
2: EX-10.1 Assignment and Consent Agreement, Dated June 6, HTML 37K
2017, Among 275 Madison Avenue Rpw 1 LLC, 275
Madison Avenue Rpw 2, LLC, Actinium
Pharmaceuticals, Inc. and Relmada Therapeutics,
Inc.
3: EX-10.3 Amended and Restated License Agreement, Dated June HTML 33K
8, 2017, Between Actinium Pharmaceuticals, Inc.
and Relmada Therapeutics, Inc.
4: EX-10.4 Offer Letter; Dated May 26, 2017, by and Between HTML 78K
Actinium Pharmaceuticals, Inc. and Dr. Nitya G.
Ray
5: EX-10.5 Amended and Restated At-The-Market Market Issuance HTML 251K
Sales Agreement, Dated July 3, 2017, Among Fbr
Capital Markets & Co., Jonestrading Institutional
Services LLC, and Mlv & Co. LLC.
6: EX-10.6 Agreement, Dated June 6, 2017, by and Between HTML 35K
Actinium Pharmaceuticals, Inc. and Sergio Traversa
7: EX-10.7 Consulting Agreement, Dated May 22, 2017, by and HTML 65K
Between Actinium Pharmaceuticals, Inc. and Dragan
Cicic
8: EX-10.8 Separation and Settlement Agreement, Dated May 12, HTML 60K
2017, by and Between Actinium Pharmaceuticals,
Inc. and Kaushik Dave
9: EX-10.9 Separation and Settlement Agreement, Dated May 12, HTML 57K
2017, by and Between Actinium Pharmaceuticals,
Inc. and Dragan Cicic
10: EX-31.1 Certification -- §302 - SOA'02 HTML 25K
11: EX-31.2 Certification -- §302 - SOA'02 HTML 25K
12: EX-32.1 Certification -- §906 - SOA'02 HTML 20K
13: EX-32.2 Certification -- §906 - SOA'02 HTML 20K
20: R1 Document and Entity Information HTML 40K
21: R2 Consolidated Balance Sheets (Unaudited) HTML 84K
22: R3 Consolidated Balance Sheets (Unaudited) HTML 37K
(Parenthetical)
23: R4 Consolidated Statements of Operations (Unaudited) HTML 53K
24: R5 Consolidated Statements of Cash Flows (Unaudited) HTML 83K
25: R6 Description of Business and Summary of Significant HTML 67K
Accounting Policies
26: R7 Related Party Transactions HTML 31K
27: R8 Prepaid Expenses and Other Current Assets HTML 26K
28: R9 Property and Equipment HTML 28K
29: R10 Derivatives HTML 47K
30: R11 Commitments and Contingencies HTML 56K
31: R12 Equity HTML 65K
32: R13 Subsequent Events HTML 24K
33: R14 Description of Business and Summary of Significant HTML 106K
Accounting Policies (Policies)
34: R15 Description of Business and Summary of Significant HTML 35K
Accounting Policies (Tables)
35: R16 Related Party Transactions (Tables) HTML 22K
36: R17 Prepaid Expenses and Other Current Assets (Tables) HTML 25K
37: R18 Property and Equipment (Tables) HTML 25K
38: R19 Derivatives (Tables) HTML 43K
39: R20 Commitments and Contingencies (Tables) HTML 30K
40: R21 Equity (Tables) HTML 44K
41: R22 Description of Business and Summary of Significant HTML 30K
Accounting Policies (Details)
42: R23 Description of Business and Summary of Significant HTML 27K
Accounting Policies (Details 1)
43: R24 Description of Business and Summary of Significant HTML 31K
Accounting Policies (Details Textual)
44: R25 Related Party Transactions (Details) HTML 25K
45: R26 Related Party Transactions (Details Textual) HTML 32K
46: R27 Prepaid Expenses and Other Current Assets HTML 30K
(Details)
47: R28 Property and Equipment (Details) HTML 34K
48: R29 Property and Equipment (Details Textual) HTML 22K
49: R30 Derivatives (Details) HTML 31K
50: R31 Derivatives (Details 1) HTML 49K
51: R32 Derivatives (Details Textual) HTML 30K
52: R33 Commitments and Contingencies (Details) HTML 39K
53: R34 Commitments and Contingencies (Details 1) HTML 35K
54: R35 Commitments and Contingencies (Details Textual) HTML 131K
55: R36 Equity (Details) HTML 69K
56: R37 Equity (Details Textual) HTML 108K
57: R38 Subsequent Events (Details) HTML 47K
59: XML IDEA XML File -- Filing Summary XML 92K
58: EXCEL IDEA Workbook of Financial Reports XLSX 47K
17: EX-101.INS XBRL Instance -- atnm-20170630 XML 744K
19: EX-101.CAL XBRL Calculations -- atnm-20170630_cal XML 87K
14: EX-101.DEF XBRL Definitions -- atnm-20170630_def XML 356K
15: EX-101.LAB XBRL Labels -- atnm-20170630_lab XML 883K
16: EX-101.PRE XBRL Presentations -- atnm-20170630_pre XML 566K
18: EX-101.SCH XBRL Schema -- atnm-20170630 XSD 126K
60: ZIP XBRL Zipped Folder -- 0001213900-17-008244-xbrl Zip 93K
 | Download this zipped .zip folder |
| Files: | atnm-20170630.xml atnm-20170630.xsd atnm-20170630_cal.xml atnm-20170630_def.xml atnm-20170630_lab.xml atnm-20170630_pre.xml |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/25/22 Actinium Pharmaceuticals, Inc. 10-K 12/31/21 56:4.2M EdgarAgents LLC/FA 3/31/21 Actinium Pharmaceuticals, Inc. 10-K 12/31/20 56:3.5M EdgarAgents LLC/FA |